Outlook Therapeutics Inc OTLK:NASDAQ

Last Price$1.57NASDAQ Closing Price as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.05(3.29%)
Bid (Size)$1.57 (145)
Ask (Size)$1.60 (2)
Day Low / High$1.51 - 1.59
Volume622.3 K
  • Latest Stories
  • Commentary and Analysis
Outlook Therapeutics Submits Biologics License Application for Wet Age-Related Macular Degeneration Treatment
10:14AM ET 3/31/2022 MT Newswires

Outlook Therapeutics (OTLK) said Thursday it submitted a biologics license application to the Food and Drug Administration for its ONS-5010 investigational...

Insider Buy: Outlook Therapeutics
5:45PM ET 2/23/2022 MT Newswires

Kurt J Hilzinger, Director, on February 22, 2022, executed a purchase for 175,132 shares in Outlook Therapeutics (OTLK) for $256,970. Following the Form 4...

--Ascendiant Capital Adjusts Price Target on Outlook Therapeutics to $7.25 From $7, Maintains Buy Rating
10:26AM ET 12/27/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Insider Buy: Outlook Therapeutics
6:18AM ET 12/02/2021 MT Newswires

Ghiath M. Sukhtian, 10% Owner, Director, on November 29, 2021, executed a purchase for 16,000,000 shares in Outlook Therapeutics (OTLK) for $20,000,000....

Outlook Therapeutics Upsizes Bought-Deal Offering of Common Shares to $50 Million
6:14AM ET 11/24/2021 MT Newswires

Outlook Therapeutics (OTLK) on Tuesday increased its previously announced bought-deal offering of common shares to $50 million in gross proceeds from the...

Outlook Therapeutics Unveils $10 Million Common Stock Offering; Shares Sink
4:51PM ET 11/23/2021 MT Newswires

Outlook Therapeutics (OTLK) said late Tuesday it agreed to a bought-deal offering of common stock allowing underwriter HC Wainwright to buy 8 million...

Outlook Therapeutics Says Ophthalmic Bevacizumab Shows 'Strong' Safety Data in Trial
3:30PM ET 10/12/2021 MT Newswires

Outlook Therapeutics (OTLK) said Tuesday its ophthalmic formulation of bevacizumab for retinal indications produced "strong" safety data consistent with...

Outlook Therapeutics' Eye Disease Drug Trial Confirms 'Strong' Safety Profile; Stock Lower
10:30AM ET 9/28/2021 MT Newswires

Outlook Therapeutics (OTLK) said Tuesday its ONS-5010 drug being developed for the potential treatment of age-related macular degeneration showed its...

Outlook Therapeutics Meets Clinical Endpoints in Phase 3 Trial of Drug to Treat Neovascular Age-Related Macular Degeneration
10:38AM ET 8/03/2021 MT Newswires

Outlook Therapeutics (OTLK) said Tuesday that ONS-5010 met both of its primary and secondary endpoints in a phase 3 trial in patients with neovascular...

Wall Street Set for Small Gains, Earnings in Focus
9:13AM ET 8/03/2021 MT Newswires

US stocks were set for a cautiously higher open Tuesday, staging a slight recovery after tumbling in the previous session as US manufacturing sentiment...